Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

recruiting133%
completed133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_2

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

NCT07183371
recruitingphase_1

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

NCT06958198
completedphase_1

Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

NCT06507605

Clinical Trials (3)

Showing 3 of 3 trials
NCT07183371Phase 2

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

Active Not Recruiting
NCT06958198Phase 1

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Recruiting
NCT06507605Phase 1

Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3